| DC8858 |
Bafilomycin A1(Baf-A1)
Featured
|
Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. |
|
| DC20740 |
BAL30072 |
BAL30072 is a monocyclic beta-lactam antibiotic that shows potent activity against MDR Pseudomonas aeruginosa and Acinetobacter sp. Isolates with MIC90 of 8 and 4 ug/ml. |
|
| DC10994 |
Balamapimod |
Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.. |
|
| DC7541 |
Balapiravir |
Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). |
|
| DC11516 |
Balovaptan
Featured
|
Balovaptan (RG7314, RG-7314) is a potent, selective vasopressin-1 receptor antagonist.. |
|
| DC11057 |
Baloxavir acid
Featured
|
Baloxavir acid (S-033447) is an anti-influenza compound that potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses. |
|
| DC9562 |
Balsalazide |
Balsalazide is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.
|
|
| DC9869 |
Bamaquimast |
Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138. |
|
| DC10385 |
BAR501
Featured
|
BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. |
|
| DC10564 |
BAR 502
Featured
|
BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively. |
|
| DC20317 |
Barbadin |
Barbadin is a small molecule that selectively inhibits the β-arrestin/β2-adaptin interaction (IC50=19.1/15.6 uM for β-arrestin1/2) without effect on the formation of receptor/β-arrestin complexes. |
|
| DC4135 |
Bardoxolone methyl
Featured
|
Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. |
|
| DC8258 |
Baricitinib phosphate
Featured
|
Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC8133 |
Batimastat(BB-94)
Featured
|
Batimastat was used to study the role of MMP in proteolytic release of EGF in human follicular thyroid carcinoma cell line FTC-133. |
|
| DC23719 |
BAY 1024767 |
BAY 1024767 (BAY1024767) is a higly potent antagonist of androgen receptor (AR) wild-type (IC50=46 nM) and mutant forms located in the AR ligand-binding domain (LBD). |
|
| DC9939 |
BAY 1082439 |
BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. |
|
| DC20750 |
BAY 1143269 |
BAY 1143269 is a potent, selective, orally bioavailable inhibitor of MNK1 with enzyme IC50 of 40 nM at 2 mM ATP. |
|
| DC10376 |
BAY-1143572 |
BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM. |
|
| DC23386 |
BAY 1238097 |
BAY 1238097 is a novel BET bromodomain inhibitor with IC50 of 50 nM, inhibits the interaction between BRD4, BRD3 or BRD2 and H4 with IC50 values of 63 nM, 609 nM and 2430 nM in the NanoBRET assay. |
|
| DC23745 |
BAY-2402234
Featured
|
BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH). |
|
| DC7782 |
BAY 41-2272 |
Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 μM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.. For the detailed information of BAY 41-2272, the solubility of BAY 41-2272 in water, the solubility of BAY 41-2272 in DMSO, the solubility of BAY 41-2272 in PBS buffer, the animal experiment (test) of BAY 41-2272, the cell expriment (test) of BAY 41-2272, the in vivo, in vitro and clinical trial test of BAY 41-2272, the EC50, IC50,and affinity,of BAY 41-2272, Please contact DC Chemicals. |
|
| DC10294 |
Bay 41-4109 |
BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. |
|
| DC10291 |
Bay 41-4109 less active enantiomer |
Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. |
|
| DC20747 |
BAY 41-8543 |
BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM). |
|
| DC7323 |
Pritelivir（BAY-57-1293）
Featured
|
BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex. |
|
| DC20748 |
BAY 60-2770 |
BAY 60-2770 is an NO-independent activator of sGC (soluble guanylyl cyclase) with EC50 of 5.4 nM. |
|
| DC23438 |
BAY 60-6583 |
BAY 60-6583 (BAY606583) is a potent, selective adenosine A2B receptor agonist with EC50 of 2.83 nM (murine A2BR). |
|
| DC9578 |
Bay 60-7550
Featured
|
Bay 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human); 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A.
|
|
| DC26066 |
BAY 61-3606 hydrochloride
Featured
|
BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase with Ki of 7.5 nM, displays no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
|
| DC11859 |
BAY85-8501 |
BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM. |
|
